PD-1/PD-L1

亜型選択性的な製品

PD-1/PD-L1 interaction PD-1 PD-L1

PD-1/PD-L1製品

All (40)
PD-1/PD-L1阻害剤 (11)
PD-1/PD-L1抗体(29)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例
A2002	Nivolumab (anti-PD-1)	Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.	Cancer Cell, 2024, S1535-6108(24)00080-1 Nat Genet, 2024, 10.1038/s41588-024-01948-8 Nat Commun, 2024, 15(1):8609
A2004	Atezolizumab (anti-PD-L1)	Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.	Nat Commun, 2024, 15(1):9723 J Immunother Cancer, 2024, 12(5)e008669 Cell Death Dis, 2024, 15(2):175
A2005	Pembrolizumab (anti-PD-1)	Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.	Nat Med, 2024, 10.1038/s41591-024-02824-y Cell Mol Immunol, 2024, 21(1):60-79 Cell Rep Med, 2024, S2666-3791(24)00196-4
S7912	BMS202	BMS202 is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM.	Phytomedicine, 2024, 125:155370 J Med Chem, 2024, 67(5):4036-4062 Mar Drugs, 2024, 22(7)303
A2013	Durvalumab (anti-PD-L1)	Durvalumab is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.	J Biol Chem, 2024, S0021-9258(24)01826-X Am J Nucl Med Mol Imaging, 2024, 14(1):31-40 Am J Nucl Med Mol Imaging, 2024, 14(1):31-40
S7911	BMS-1	BMS-1 is a small-molecule inhibitor of PD-1/PD-L1 interaction with IC50 of 6 nM.	J Med Chem, 2024, 67(5):4036-4062 PLoS Comput Biol, 2024, 20(11):e1012284 Int. J. Mol. Sci, 2023, 24(4)
S8158	PD-1/PD-L1 Inhibitor 3	PD-1/PD-L1 Inhibitor 3（Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3）is a Macrocyclic inhibitor of PD-1/PD-L1 interaction with IC50 of 5.6 nM	ACS Appl Mater Interfaces, 2024, 16(18):22839-49 J Med Chem, 2024, 67(5):4036-4062 Pharmaceuticals (Basel), 2023, 16(7)1051
S8275	Tomivosertib (eFT-508)	Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.	J Clin Invest, 2024, 134(16)e168393 Sci Adv, 2024, 10(37):eadi7673 PLoS Biol, 2023, 21(8):e3002227
S8859	BMS-1166	BMS-1166 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 interaction with an IC50 of 1.4 nM.	Life Sci Alliance, 2024, 10.26508/lsa.202302461 Biomed Res, 2024, 45(5):179-186 Int J Biol Sci, 2023, 19(14):4627-4643
S8549	AUNP-12	AUNP-12 (Aur-012, Aurigene-012, Aurigene NP-12), a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.	Acta Pharm Sin B, 2024, 14(1):350-364 Carcinogenesis, 2022, bgac043 Molecules, 2019, 24(15)
A2015	Avelumab (anti-PD-L1)	Avelumab (anti-PD-L1) (MSB0010718C) is a fully human IgG1 monoclonal antibody that targets the protein programmed death-ligand 1 (PD-L1). Avelumab exhibits potential antibody-dependent cell-mediated cytotoxicity and is used for the treatment of several kinds of carcinoma. MW=143.8 kDa.	J Biol Chem, 2024, S0021-9258(24)01826-X Viruses, 2021, 13(10)2017
A2115	Anti-mouse PD-L1 (B7-H1)-InVivo	Anti-mouse PD-L1 (B7-H1)-InVivo (Clone:10F.9G2) monoclonal antibody reacts with mouse PD-L1 (also known as B7-H1, CD274). The 10F.9G2 antibody has been shown to block the interaction between PD-L1 and PD-1 and between PD-L1 and B7-1 (CD80).	Cancer Commun (Lond), 2024, 10.1002/cac2.12545 Cancer Commun (Lond), 2024, 44(6):670-694 Biomaterials, 2024, 312:122714
S0094	SR 0987	SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. SR 0987 represses PD-1, produces IL17 and is potential for the treatment of cancer.	Evid Based Complement Alternat Med, 2022, 2022:8315503
A2017	Spartalizumab (anti-PD-1)	Spartalizumab is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1, MW: 145.8 KD.	Elife, 2020, 9
E1322	GS-4224	GS-4224 (Evixapodlin, PD-1/PD-L1-IN 7) is an inhibitor of human PD-1/PD-L1 protein/protein interaction with an IC50 of 0.213 nM. It enhances IFN-γ and Granzyme B Production in chronic hepatitis B (CHB) CD8+ T Cells and CD4+ T Cells. It exhibits anticancer and antiviral functions.
A2381	Serplulimab (Anti-PDCD1 / PD-1 / CD279)	Serplulimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.5 kD.
A2835	Dostarlimab (Anti-PDCD1 / PD-1 / CD279)	Dostarlimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 ((PD-1 programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.18 KD.
A2165^New	Anti-mouse PD-1 (CD279)(29F.1A12)-InVivo
A2156^New	Anti-human PD-L1 (B7-H1)-InVivo	Anti-human PD-L1 (B7-H1)-InVivo reacts with human PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily.
S8473	CA-170 (AUPM-170)	CA-170 (AUPM-170, PD-1-IN-1 ) is potent and orally available inhibitor of the immune checkpoint regulatory proteins PD-L1 (programmed cell death ligand-1) and VISTA (V-domain immunoglobulin (Ig) suppressor of T-cell activation). CA-170 exhibits anti-tumor efficacy.
A2858	Finotonlimab (Anti-PDCD1 / PD-1 / CD279)	Finotonlimab (Anti-PDCD1 / PD-1 / CD279) is a recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1, PDCD1, CD279) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.38 KD.
A2022	Cemiplimab (anti-PD-1)	Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response.	Life Sci Alliance, 2024, 7(3)e202302368
A2613	Anti-B7-H1 / PD-L1 / CD274 (MDX-1105)	Anti-B7-H1 / PD-L1 / CD274 (MDX-1105) is a fully humanized monoclonal antibody targeting B7-H1. It is used in research of advanced melanoma, non-small cell lung carcinoma, renal cell carcinoma, and ovarian cancer. MW :150 KD.
A2882	Geptanolimab (Anti-PDCD1 / PD-1 / CD279)	Geptanolimab (Anti-PDCD1 / PD-1 / CD279) is an immunoglobulin G4 (IgG4) humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PD1, PDCD1, CD279) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 144.4 KD.
A2913	Iparomlimab (Anti-PDCD1 / PD-1 / CD279)	Iparomlimab (Anti-PDCD1 / PD-1 / CD279) is a human IgG4κ monoclonal antibody targated against PD-1/CD279/PDCD1. Iparomlimab can be used for oncology research. MW: 144.18 KD.
A2122	Anti-mouse PD-1 (CD279)-InVivo	Anti-mouse PD-1 (CD279)-InVivo (Clone:RMP1-14)reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily.	J Immunother Cancer, 2024, 12(8)e009024 Cancer Lett, 2024, 588:216814 Cell Rep, 2024, 43(11):114962
A2923	Lodapolimab (Anti-B7-H1 / PD-L1 / CD274)	Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human IgG1λ monoclonal antibody that binds to human PD-L1 with high affinity and inhibits interactions of PD-L1 with its two cognate receptors, PD-1 and CD80. MW: 143.86 KD.
A2956	Nofazinlimab (Anti-PDCD1 / PD-1 / CD279)	Nofazinlimab (anti-PDCD1/ PD-1 / CD279) is a humanised IgG4 monoclonal antibody targeting PD-1. Nofazinlimab has the potential to be used in unresectable hepatocellular carcinoma (uHCC) research. MW: 145.08 KD.
A2998	Opucolimab (Anti-B7-H1 / PD-L1 / CD274)	Opucolimab (Anti-B7-H1 / PD-L1 / CD274) is a recombinant human monoclonal antibody targeting PD-L1. It can be used for the research of advanced solid tumors. MW :144.68 KD.
S9610	BMS-1001	BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes.
A2035	Sintilimab (anti-PD-1)	Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells.	J Immunother Cancer, 2024, 12(9)e009603
S9863	INCB086550	INCB086550 (PD-1/PD-L1-IN-8) is a potent PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM. INCB086550 binds to PD-L1 and interrupts its interaction with PD-1 and also induces PD-L1 dimerization and internalization.
A2775	Adebrelimab (Anti-B7-H1 / PD-L1 / CD274)	Adebrelimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G4 (IgG4) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1, cluster of differentiation 274, CD274) with promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC). MW: 145.8 kD.
A2778	Garivulimab (Anti-B7-H1 / PD-L1 / CD274)	Garivulimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 144.3 KD.
A2780	Manelimab (Anti-B7-H1 / PD-L1 / CD274)	Manelimab (Anti-B7-H1 / PD-L1 / CD274) is a monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 143.68 kD.
A2781	Pacmilimab (Anti-B7-H1 / PD-L1 / CD274)	Pacmilimab (anti-B7-H1 / PD-L1 / CD274) is a monoclonal antibody directed against the tumor-associated antigen (TAA) programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 152.6 kD.
A2782	Sudubrilimab (Anti-B7-H1 / PD-L1 / CD274)	Sudubrilimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1-kappa, anti-(homo sapiens CD274 (programmed death ligand 1, PDL1, pd-l1, B7 homolog 1, B7H1)), monoclonal antibody. MW: 144.6 kD.
A2783	Sugemalimab (Anti-B7-H1 / PD-L1 / CD274)	Sugemalimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small-cell lung cancer research. MW: 143.36 kD.
A2016	Camrelizumab (anti-PD-1)	Camrelizumab is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1 with immune checkpoint inhibitory and antineoplastic activities, MW: 146.3 KD.	Life Sci Alliance, 2024, 7(3)e202302368
A2811	Cosibelimab (Anti-B7-H1 / PD-L1 / CD274)	Cosibelimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1 (IgG1), human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.64 KD.
S7912	BMS202	BMS202 is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM.	Phytomedicine, 2024, 125:155370 J Med Chem, 2024, 67(5):4036-4062 Mar Drugs, 2024, 22(7)303
S7911	BMS-1	BMS-1 is a small-molecule inhibitor of PD-1/PD-L1 interaction with IC50 of 6 nM.	J Med Chem, 2024, 67(5):4036-4062 PLoS Comput Biol, 2024, 20(11):e1012284 Int. J. Mol. Sci, 2023, 24(4)
S8158	PD-1/PD-L1 Inhibitor 3	PD-1/PD-L1 Inhibitor 3（Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3）is a Macrocyclic inhibitor of PD-1/PD-L1 interaction with IC50 of 5.6 nM	ACS Appl Mater Interfaces, 2024, 16(18):22839-49 J Med Chem, 2024, 67(5):4036-4062 Pharmaceuticals (Basel), 2023, 16(7)1051
S8275	Tomivosertib (eFT-508)	Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.	J Clin Invest, 2024, 134(16)e168393 Sci Adv, 2024, 10(37):eadi7673 PLoS Biol, 2023, 21(8):e3002227
S8859	BMS-1166	BMS-1166 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 interaction with an IC50 of 1.4 nM.	Life Sci Alliance, 2024, 10.26508/lsa.202302461 Biomed Res, 2024, 45(5):179-186 Int J Biol Sci, 2023, 19(14):4627-4643
S8549	AUNP-12	AUNP-12 (Aur-012, Aurigene-012, Aurigene NP-12), a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.	Acta Pharm Sin B, 2024, 14(1):350-364 Carcinogenesis, 2022, bgac043 Molecules, 2019, 24(15)
S0094	SR 0987	SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. SR 0987 represses PD-1, produces IL17 and is potential for the treatment of cancer.	Evid Based Complement Alternat Med, 2022, 2022:8315503
E1322	GS-4224	GS-4224 (Evixapodlin, PD-1/PD-L1-IN 7) is an inhibitor of human PD-1/PD-L1 protein/protein interaction with an IC50 of 0.213 nM. It enhances IFN-γ and Granzyme B Production in chronic hepatitis B (CHB) CD8+ T Cells and CD4+ T Cells. It exhibits anticancer and antiviral functions.
S8473	CA-170 (AUPM-170)	CA-170 (AUPM-170, PD-1-IN-1 ) is potent and orally available inhibitor of the immune checkpoint regulatory proteins PD-L1 (programmed cell death ligand-1) and VISTA (V-domain immunoglobulin (Ig) suppressor of T-cell activation). CA-170 exhibits anti-tumor efficacy.
S9610	BMS-1001	BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes.
S9863	INCB086550	INCB086550 (PD-1/PD-L1-IN-8) is a potent PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM. INCB086550 binds to PD-L1 and interrupts its interaction with PD-1 and also induces PD-L1 dimerization and internalization.
A2002	Nivolumab (anti-PD-1)	Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.	Cancer Cell, 2024, S1535-6108(24)00080-1 Nat Genet, 2024, 10.1038/s41588-024-01948-8 Nat Commun, 2024, 15(1):8609
A2004	Atezolizumab (anti-PD-L1)	Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.	Nat Commun, 2024, 15(1):9723 J Immunother Cancer, 2024, 12(5)e008669 Cell Death Dis, 2024, 15(2):175
A2005	Pembrolizumab (anti-PD-1)	Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.	Nat Med, 2024, 10.1038/s41591-024-02824-y Cell Mol Immunol, 2024, 21(1):60-79 Cell Rep Med, 2024, S2666-3791(24)00196-4
A2013	Durvalumab (anti-PD-L1)	Durvalumab is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.	J Biol Chem, 2024, S0021-9258(24)01826-X Am J Nucl Med Mol Imaging, 2024, 14(1):31-40 Am J Nucl Med Mol Imaging, 2024, 14(1):31-40
A2015	Avelumab (anti-PD-L1)	Avelumab (anti-PD-L1) (MSB0010718C) is a fully human IgG1 monoclonal antibody that targets the protein programmed death-ligand 1 (PD-L1). Avelumab exhibits potential antibody-dependent cell-mediated cytotoxicity and is used for the treatment of several kinds of carcinoma. MW=143.8 kDa.	J Biol Chem, 2024, S0021-9258(24)01826-X Viruses, 2021, 13(10)2017
A2115	Anti-mouse PD-L1 (B7-H1)-InVivo	Anti-mouse PD-L1 (B7-H1)-InVivo (Clone:10F.9G2) monoclonal antibody reacts with mouse PD-L1 (also known as B7-H1, CD274). The 10F.9G2 antibody has been shown to block the interaction between PD-L1 and PD-1 and between PD-L1 and B7-1 (CD80).	Cancer Commun (Lond), 2024, 10.1002/cac2.12545 Cancer Commun (Lond), 2024, 44(6):670-694 Biomaterials, 2024, 312:122714
A2017	Spartalizumab (anti-PD-1)	Spartalizumab is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1, MW: 145.8 KD.	Elife, 2020, 9
A2381	Serplulimab (Anti-PDCD1 / PD-1 / CD279)	Serplulimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.5 kD.
A2835	Dostarlimab (Anti-PDCD1 / PD-1 / CD279)	Dostarlimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 ((PD-1 programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.18 KD.
A2165^New	Anti-mouse PD-1 (CD279)(29F.1A12)-InVivo
A2156^New	Anti-human PD-L1 (B7-H1)-InVivo	Anti-human PD-L1 (B7-H1)-InVivo reacts with human PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily.
A2858	Finotonlimab (Anti-PDCD1 / PD-1 / CD279)	Finotonlimab (Anti-PDCD1 / PD-1 / CD279) is a recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1, PDCD1, CD279) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.38 KD.
A2022	Cemiplimab (anti-PD-1)	Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response.	Life Sci Alliance, 2024, 7(3)e202302368
A2613	Anti-B7-H1 / PD-L1 / CD274 (MDX-1105)	Anti-B7-H1 / PD-L1 / CD274 (MDX-1105) is a fully humanized monoclonal antibody targeting B7-H1. It is used in research of advanced melanoma, non-small cell lung carcinoma, renal cell carcinoma, and ovarian cancer. MW :150 KD.
A2882	Geptanolimab (Anti-PDCD1 / PD-1 / CD279)	Geptanolimab (Anti-PDCD1 / PD-1 / CD279) is an immunoglobulin G4 (IgG4) humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PD1, PDCD1, CD279) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 144.4 KD.
A2913	Iparomlimab (Anti-PDCD1 / PD-1 / CD279)	Iparomlimab (Anti-PDCD1 / PD-1 / CD279) is a human IgG4κ monoclonal antibody targated against PD-1/CD279/PDCD1. Iparomlimab can be used for oncology research. MW: 144.18 KD.
A2122	Anti-mouse PD-1 (CD279)-InVivo	Anti-mouse PD-1 (CD279)-InVivo (Clone:RMP1-14)reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily.	J Immunother Cancer, 2024, 12(8)e009024 Cancer Lett, 2024, 588:216814 Cell Rep, 2024, 43(11):114962
A2923	Lodapolimab (Anti-B7-H1 / PD-L1 / CD274)	Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human IgG1λ monoclonal antibody that binds to human PD-L1 with high affinity and inhibits interactions of PD-L1 with its two cognate receptors, PD-1 and CD80. MW: 143.86 KD.
A2956	Nofazinlimab (Anti-PDCD1 / PD-1 / CD279)	Nofazinlimab (anti-PDCD1/ PD-1 / CD279) is a humanised IgG4 monoclonal antibody targeting PD-1. Nofazinlimab has the potential to be used in unresectable hepatocellular carcinoma (uHCC) research. MW: 145.08 KD.
A2998	Opucolimab (Anti-B7-H1 / PD-L1 / CD274)	Opucolimab (Anti-B7-H1 / PD-L1 / CD274) is a recombinant human monoclonal antibody targeting PD-L1. It can be used for the research of advanced solid tumors. MW :144.68 KD.
A2035	Sintilimab (anti-PD-1)	Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells.	J Immunother Cancer, 2024, 12(9)e009603
A2775	Adebrelimab (Anti-B7-H1 / PD-L1 / CD274)	Adebrelimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G4 (IgG4) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1, cluster of differentiation 274, CD274) with promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC). MW: 145.8 kD.
A2778	Garivulimab (Anti-B7-H1 / PD-L1 / CD274)	Garivulimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 144.3 KD.
A2780	Manelimab (Anti-B7-H1 / PD-L1 / CD274)	Manelimab (Anti-B7-H1 / PD-L1 / CD274) is a monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 143.68 kD.
A2781	Pacmilimab (Anti-B7-H1 / PD-L1 / CD274)	Pacmilimab (anti-B7-H1 / PD-L1 / CD274) is a monoclonal antibody directed against the tumor-associated antigen (TAA) programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 152.6 kD.
A2782	Sudubrilimab (Anti-B7-H1 / PD-L1 / CD274)	Sudubrilimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1-kappa, anti-(homo sapiens CD274 (programmed death ligand 1, PDL1, pd-l1, B7 homolog 1, B7H1)), monoclonal antibody. MW: 144.6 kD.
A2783	Sugemalimab (Anti-B7-H1 / PD-L1 / CD274)	Sugemalimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small-cell lung cancer research. MW: 143.36 kD.
A2016	Camrelizumab (anti-PD-1)	Camrelizumab is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1 with immune checkpoint inhibitory and antineoplastic activities, MW: 146.3 KD.	Life Sci Alliance, 2024, 7(3)e202302368
A2811	Cosibelimab (Anti-B7-H1 / PD-L1 / CD274)	Cosibelimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1 (IgG1), human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.64 KD.
A2165^New	Anti-mouse PD-1 (CD279)(29F.1A12)-InVivo
A2156^New	Anti-human PD-L1 (B7-H1)-InVivo	Anti-human PD-L1 (B7-H1)-InVivo reacts with human PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily.

PD-1/PD-L1阻害剤の選択性比較